Importer of Controlled Substances; Notice of Application, 30330-30331 [2013-12117]

Download as PDF 30330 Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices TKELLEY on DSK3SPTVN1PROD with NOTICES Therefore, in accordance with 21 CFR § 1301.34(a), this is notice that on December 20, 2011, Wildlife Laboratories Inc., 1401 Duff Drive, Suite 400, Fort Collins, Colorado 80524, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of Etorphine (except HCl) (9056), a basic class of controlled substance listed in schedule I. The company plans to manufacture the above listed controlled substance for sale to zoo and wildlife veterinarian zoos and, for use with other animal and wildlife applications. Any bulk manufacturers who are presently, or are applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 21, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745, all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–12109 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 16:59 May 21, 2013 Jkt 229001 DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application; Alltech Associates, Inc. Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on March 28, 2013, Alltech Associates, Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Gamma Hydroxybutyric Acid (2010). Lysergic acid diethylamide (7315) Heroin (9200) ............................... Cocaine (9041) ............................. Codeine (9050) ............................. Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Fmt 4703 [FR Doc. 2013–12120 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration I Importer of Controlled Substances; Notice of Application I I II II II II II II Pursuant to Title 21, Code of Federal Regulations 1301.34 (a), this is notice that on April 10, 2013, Arizona Department of Corrections, ASPCFlorence, 1305 E. Butte Avenue, Florence, Arizona 85132, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Pentobarbital (2270), a basic class of controlled substance listed in schedule II. The facility intends to import the above listed controlled substance for legitimate use. Supplies of this particular controlled substance are inadequate and are not available in the form needed within the current domestic supply of the United States. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedules I and II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 21, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted The company plans to import these controlled substances for the manufacture of reference standards. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I and II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 21, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic classes of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Frm 00064 Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Schedule Drug PO 00000 Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Sfmt 4703 E:\FR\FM\22MYN1.SGM 22MYN1 30331 Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–12117 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; Meridian Medical Technologies By Notice dated March 7, 2012, and published in the Federal Register on March 13, 2013, 78 FR 15974, Meridian Medical Technologies, 2555 Hermelin Drive, St. Louis, Missouri 63144, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Morphine (9300), a basic class of controlled substance listed in schedule II. The company manufactures a product containing morphine in the United States. The company exports this product to customers around the world. The company has been asked to ensure that its product sold to European customers meets standards established by the European Pharmacopeia, which is administered by the Directorate of the Quality of Medicines (EDQM). In order to ensure that its product will meet European specifications, the company seeks to import morphine supplied by EDQM to use as reference standards. This is the sole purpose for which the company will be authorized by DEA to import morphine. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Meridian Medical Technologies to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Meridian Medical Technologies to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR § 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: May 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–12121 Filed 5–21–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Alltech Associates, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 28, 2013, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: TKELLEY on DSK3SPTVN1PROD with NOTICES Drug Schedule Methcathinone (1237) .................................................................................................................................................................................. N-Ethylamphetamine (1475) ........................................................................................................................................................................ N,N-Dimethylamphetamine (1480) .............................................................................................................................................................. 4-Methylaminorex (cis isomer) (1590) ......................................................................................................................................................... Alpha-ethyltryptamine (7249) ...................................................................................................................................................................... Lysergic acid diethylamide (7315) ............................................................................................................................................................... 2C-T-7 (2,5-Dimethoxy-4-(n)-Propylthiophenethylamine) (7348) ................................................................................................................ Tetrahydrocannabinols (7370) ..................................................................................................................................................................... Mescaline (7381) ......................................................................................................................................................................................... 2C-T-2 (2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine)(7385) ................................................................................................................ 4-Bromo-2,5-dimethoxyamphetamine (7391) .............................................................................................................................................. 4-Bromo-2,5-dimethoxyphenethylamine (7392) .......................................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine (7395) .............................................................................................................................................. 2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................ 2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................ 3,4-Methylenedioxyamphetamine (7400) .................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .................................................................................................................................. 3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................ 3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................ 4-Methoxyamphetamine (7411) ................................................................................................................................................................... 5-Methoxy-N-N-dimethyltryptamine (7431) ................................................................................................................................................. Alpha-methyltryptamine (7432) ................................................................................................................................................................... Bufotenine (7433) ........................................................................................................................................................................................ Diethyltryptamine (7434) ............................................................................................................................................................................. Dimethyltryptamine (7435) .......................................................................................................................................................................... Psilocybin (7437) ......................................................................................................................................................................................... Psilocyn (7438) ............................................................................................................................................................................................ 5-Methoxy-N,N-diisopropyltryptamine (7439) .............................................................................................................................................. N-Ethyl-1-phenylcyclohexylamine (7455) .................................................................................................................................................... 1-(1-Phenylcyclohexyl)pyrrolidine (7458) .................................................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ............................................................................................................................................... VerDate Mar<15>2010 16:59 May 21, 2013 Jkt 229001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\22MYN1.SGM 22MYN1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I

Agencies

[Federal Register Volume 78, Number 99 (Wednesday, May 22, 2013)]
[Notices]
[Pages 30330-30331]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12117]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to Title 21, Code of Federal Regulations 1301.34 (a), this 
is notice that on April 10, 2013, Arizona Department of Corrections, 
ASPC-Florence, 1305 E. Butte Avenue, Florence, Arizona 85132, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of Pentobarbital (2270), a basic class of 
controlled substance listed in schedule II.
    The facility intends to import the above listed controlled 
substance for legitimate use. Supplies of this particular controlled 
substance are inadequate and are not available in the form needed 
within the current domestic supply of the United States.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance listed in schedules I and II, which falls under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than June 21, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted

[[Page 30331]]

in a previous notice published in the Federal Register on September 23, 
1975, 40 FR 43745-46, all applicants for registration to import a basic 
class of any controlled substance in schedules I or II are, and will 
continue to be, required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, that the requirements for such registration pursuant to 
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), 
(e), and (f) are satisfied.

    Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-12117 Filed 5-21-13; 8:45 am]
BILLING CODE 4410-09-P